UnknownPhase 2

Statin Treatment for UnruptureD Intracranial anEurysms Study

China60 participantsStarted 2019-11-07

Plain-language summary

This study was designed to identify whether there is a measurable reduction in inflammation in walls of intracranial aneurysms with oral atorvastatin.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Be aged 18 or over, male or non-pregnant female;
✓. patients have a saccular UIA identified on imaging (CT, MRI or DSA), and the aneurysm ≥3mm;
✓. patients with wall enhancement of aneurysm by MRI VWI before treatment;
✓. patients who is able to understand the objective of the trial, agrees and signs the written informed consent form.

Exclusion criteria

✕. Patient with MRI contraindications: metallic implant, contrast allergy, claustrophobia, etc.;
✕. Planned treatment of the aneurysm within 6 months;
✕. Patient taking the drugs, which might have an anti-inflammatory effect, such as aspirin, statin, immunosuppressive drug, etc.
✕. Dyslipidemia or severely impaired liver or renal functions
✕. Retreatment of recurrent aneurysm;
✕. Pregnant or lactating women;
✕. Patients with malignant diseases, such as liver disease, kidney disease, congestive heart failure, malignant tumors, etc;
✕. Poor compliance patients.

What they're measuring

The change in aneurysm wall inflammation as measured by MRI vessel wall imaging (VWI).

Timeframe: 6 months

Trial details

NCT IDNCT04149483

SponsorBeijing Neurosurgical Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-02-01

Contact for this trial

Yisen Zhang, MD

+86-010-59978852 zhang-yisen@163.com

View on ClinicalTrials.gov More Intracranial Aneurysm trials